Horizon2020
SC1 – Health, Demographic change and Wellbeing - Opportunità per l’area “Salute (2016-2017)”

Caterina BUONOCORE
Bruno MOURENZA
Horizon 2020
Punto di Contatto Nazionale SC1
Coordinatore dei PCN in APRE
AGENDA

• Contesto H2020
• Opportunità in Salute
• Programmazione dei prossimi 3 anni di H2020 – per la SC1
Health R&D in Europe and in US

- US - Health R&D = 30% of Civil public R&D
- EU – Health R&D = 8% of Civil public R&D
- H2020 – Health (SC1) = 10% of H2020 total
<table>
<thead>
<tr>
<th>Collaborative health research (SC1)</th>
<th>Public-private partnership</th>
<th>Frontier research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support to innovation</td>
<td>Modelling &amp; predictive (neuro)sciences</td>
<td>Research Education Innovation</td>
</tr>
<tr>
<td>Health research infrastructures</td>
<td>Loans for de-risking R&amp;I</td>
<td>Deployment of innovative solutions</td>
</tr>
</tbody>
</table>

**Health research in Horizon 2020**
H2020/ The Three Pillars

- Excellent science
- Industrial leadership
- Societal challenges
Various instruments along the value chain
Excellent Science
- European Research Council
  - Frontier research by the best individual teams
- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation
- Marie Skłodowska Curie actions
  - Opportunities for training and career development
- Research infrastructures
  (including e-infrastructure)
  - Ensuring access to world-class facilities

Industrial Technologies
- Leadership in enabling and industrial technologies
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Secure societies

European Institute of Innovation and Technology (EIT)
Spreading Excellence and Widening Participation
Science with and for society
Joint Research Center (JRC)
STRUCTURE OF THE PROGRAMME: WHERE HEALTH could fit?

- ERC
- MSCA
- SME Instrument
- SC1, 2, 3, 7...

GROUP of Researchers/actors doing collaborative multidisciplinary research

ONE or more SME developing solutions close to market

INDIVIDUAL RESEARCHER doing High risk/frontier Research

INDIVIDUAL RESEARCHER targeting dev. of research career and training

GROUP of researchers/actors doing research on Key enabling Technologies

GROUP of researchers/actors doing basic/visionary but feasible research on technological aspects

NMP-b

ICT

Materials

FET

www.apre.it
2° PILLAR

INDUSTRIAL LEADERSHIP
Connections to Health in Pillar II

**Industrial Technologies**

- **Leadership in enabling and industrial technologies**
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space

- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation

- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs
**[Health opportunities in ICT]**

**ICT-11-2017: Collective Awareness Platforms for Sustainability and Social Innovation**
To demonstrating new forms of bottom-up innovation and social collaboration exploiting digital hyper-connectivity and collaborative tools based on open data, open knowledge, open source software and open hardware.

Proposal may suggest replicable solutions by using existing or very near-to-market technologies. They may ensure strong industrial domain, possibility to embrace cross-domain activities, to demonstrate data harvesting and analytics added value in industrial ecosystems. Possible industrial sectors include health.

**ICT-27-2017: System abilities, SME & benchmarking actions, safety certification (scope c.)**
Developing and testing protocols for shared space cooperative and collaborative systems leading to viable safety certification standards. Potential proposals may include healthcare and elderly or handicapped care applications.

**ICT-30-2017: Photonics KET 2017 (scope b.)**
Biophotonics: imaging systems for in-depth disease diagnosis. The objective is the demonstration and validation in real-settings of innovative, easy to operate, compact, and non- or minimally invasive imaging systems to support diagnosis of age and lyfe-style related diseases.

→ **Deadline: 25 April 2017**
Proposal Template: 70 pages (single step)

---

**Idealist – H2020 ICT/FET NCP Network**
### Health topics in II PILLAR: NMP

#### Excellent Science
- European Research Council
  - Frontier research by the best individual teams
- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation
- Marie Skłodowska Curie actions
  - Opportunities for training and career development
- Research infrastructures (including e-infrastructure)
  - Ensuring access to world-class facilities

#### Industrial Technologies
- **Leadership in enabling and industrial technologies**
  - ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs

#### Societal Challenges
- **Health, demographic change and wellbeing**
- **Food security, sustainable agriculture, marine and maritime research & the bioeconomy**
- **Secure, clean and efficient energy**
- **Smart, green and integrated transport**
- **Climate action, resource efficiency and raw materials**
- **Inclusive, innovative and reflective societies**
- **Security society**

#### Advanced Materials and Nanotechnologies for Healthcare
*From topics NMBP 12 to 16*

<table>
<thead>
<tr>
<th>Year</th>
<th>Topic</th>
<th>Topic Title</th>
<th>Instrument</th>
<th>TRL</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>NMBP 13-2017</td>
<td>Cross-cutting KETs for diagnostics at the point-of-care</td>
<td>RIA</td>
<td>3/4-5/6</td>
<td>19/1/17</td>
</tr>
<tr>
<td></td>
<td>NMBP 16-2017</td>
<td>Mobilising the European nano-biomedical ecosystem</td>
<td>CSA</td>
<td></td>
<td>19/1/17</td>
</tr>
</tbody>
</table>

**NMP TeAM – H2020 NMP NCP Network**
http://www.nmpTEAM.eu/
3° PILLAR

SOCIETAL CHALLENGES
HEALTH implications in Societal Challenges

Societal Challenges

- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society
### Excellent Science
- European Research Council
- Future and Emerging Technologies
- Marie Skłodowska Curie actions
- Research infrastructures (including e-infrastructure)

### Industrial Technologies
- Leadership in enabling and industrial technologies
- ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
- Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
- Fostering all forms of innovation in all types of SMEs

### Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

### Healthy and safe foods and diets for all
- **SFS-39-2017**: How to tackle the childhood obesity epidemic.
- **SFS-40-2017**: Sweeteners and sweetness enhancers.

### Linking healthy oceans and seas for healthy people
- **BG-06-2017**: Interaction between people, oceans and seas: a strategic approach towards healthcare and well-being
- **BG-07-2017**: Blue green innovation for clean coasts and seas.
- **BG-08-2017**: Innovative sustainable solutions for improving the safety and dietary properties of seafood

---

**BIO Horizon–H2020 SC2/BIO NCP Network**

http://www.ncp-biohorizon.net/start
**Societal Challenge 7- Security**

**Excellent Science**
- European Research Council
- Future and Emerging Technologies
- Marie Skłodowska Curie actions
- Research infrastructures (including e-infrastructure)

**Industrial Technologies**
- Leadership in enabling and industrial technologies
  - ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

**Societal Challenges**
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

---

**SEREN3 – H2020 SC7NCP Network**
http://www.seren-project.eu/

---

<table>
<thead>
<tr>
<th>Year</th>
<th>Topic</th>
<th>Topic Title</th>
<th>Instrument</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>CIP 01- 2016-2017</td>
<td>Prevention, detection, response, mitigation of the combination of physical and cyber threats to the critical infrastructure of Europe (including Health Services)</td>
<td>IA</td>
<td>24/08/17</td>
</tr>
</tbody>
</table>
SC1. HEALTH, DEMOGRAPHIC CHANGE AND WELLBEING
Work Programme SC1 2016-2017

- Pers. Medicine
- Broad topics
- Less prescriptive topic texts
- Two-year work programme
- Stronger focus on end users
- Clinical trials
Personalised medicine – towards a definition

"Personalised medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention"
The Screening to Improve Health In very Preterm InfantS in Europe (SHIPS) project aims to improve follow-up programmes in Europe by studying their impact on children and their families. Follow-up screening and prevention programmes identify health problems early, enable interventions to improve health and development and allow optimal management of health care.

EMILIA-ROMAGNA AND LAZIO

Two of the three EPICE regions are included in the SHIPS project in Italy: Emilia-Romagna and Lazio. Both have on-going data collection on all newborns below 32 weeks of gestational age, or below a birth weight of 1500 g. The Bambino Gesù Pediatric Hospital (OPBG) is responsible for the data collection in both Lazio and Emilia-Romagna.

Bambino Gesù Pediatric Hospital (OPBG)

The Clinical Care and Management Innovation Research Area at OPBG carries out research in perinatal epidemiology and follow-up of high risk infants; quality of life in patients with chronic conditions; evaluation of health care; clinical and research ethics. It also carries out qualitative research related to health care practices and quality of life.
The PICASO project is developing an ICT platform to support coordination of care plans for people diagnosed with co-occurring chronic diseases. The PICASO project aims to develop information and communication technologies which meet these demands, by supporting a continuum of care from hospitals and outpatient clinic to the home. The PICASO platform will enable the sharing of a patient's complete care pathways with tools to establish health status, predict risks and adjust care. Based on monitoring of different physiological parameters at home, the patients can actively participate in their own care. The result is better management of co-existing diseases and coordination of care plans for the benefit of patients and carers across organisations.

In PICASO, UTV coordinates and conducts the integrated care trial at UTV, appropriately addressing the complex Parkinson-CVD and related co-morbidities and the exploration of integrated care models with non-professional carers which is common in Mediterranean countries. The Department of Biomedicine and Prevention focuses on clinical and empirical research in the areas of personalised medicine, genetic medicine, nanomaterials and diagnostic imaging with dedicated laboratories and research programs.
LSFM4LIFE intends to bridge the “valley of death” from the idea human pancreas organoids for the T1D therapy to the application GMP-level organoids ready for the implementation of the clinical phases.
## SC1 topics – 2017

<table>
<thead>
<tr>
<th>Call</th>
<th>Budget</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SC1-PM-03–2017:</strong></td>
<td>€15M</td>
<td>11 Apr. 2017</td>
</tr>
<tr>
<td>Diagnostic characterisation of rare disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SC1-PM-11–2017:</strong></td>
<td>€30M</td>
<td>11 Apr. 2017</td>
</tr>
<tr>
<td>Clinical research on regenerative medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personalised coaching for well-being and care of people as they age</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SC1-PM-16–2017:</strong></td>
<td>€19M</td>
<td>14 Mar. 2017</td>
</tr>
<tr>
<td>In-silico trials for developing and assessing biomedical products</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SC1-PM-17 – 2017:</strong></td>
<td>€19M</td>
<td>14 Mar. 2017</td>
</tr>
<tr>
<td>Personalised computer models and in-silico systems for well-being</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SC1-PM-19–2017:</strong></td>
<td>€8.26M</td>
<td>14 Mar. 2017</td>
</tr>
<tr>
<td>PPI for uptake of standards for the exchange of digitalised healthcare records</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SC1-PM-20-2017:</strong></td>
<td>€9M</td>
<td>11 Apr. 2017</td>
</tr>
<tr>
<td>Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## SC1 topics – 2017 – Other actions

<table>
<thead>
<tr>
<th>Call</th>
<th>Budget</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SC1-HCO-08–2017:</strong> Actions to bridge the divide in European health research and innovation</td>
<td>€1M</td>
<td>11 Apr. 2017</td>
</tr>
<tr>
<td><strong>InnovFin Infectious Diseases (InnovFin ID) Pilot</strong></td>
<td>€50M (2016) €50M (2017)</td>
<td>From first quarter of 2016</td>
</tr>
<tr>
<td><strong>Inducement prize on reducing maternal and new-born morbidity and mortality - the Birth Day Prize</strong></td>
<td>€1M</td>
<td>2017</td>
</tr>
</tbody>
</table>

**SC1 Work Programme** (updated at 25 July 2016)

SC1 and international cooperation

• Reference to specific multi-lateral initiatives

• Mutual opening of research programmes with Third Countries (USA)

• Funding of Third Countries entities by their own funding agencies for participating to Horizon 2020 (Switzerland, Australia)

• Specific actions
Programmazione dei prossimi 3 anni di H2020
SC1 2018-2020
Next SC1 Work Programme 2018-2020

VERTICAL themes
1. Personalised medicine
2. Rare diseases
3. Infectious diseases
4. Non-communicable diseases
5. Paediatrics
6. Public health and prevention including migration
7. Active and healthy ageing

HORIZONTAL themes
8. Big data
9. eHealth, mHealth, ICT
10. Integration of care
11. Environment and health, green solutions and sustainability including climate change

CROSS-CUTTING issues
12. Social Sciences and Humanities, integration, inequalities, migration and ethics
13. Sex and gender differences in medicine
14. Commercialisation within “Health, Demographic Change and Well-being”
15. Encouraging stronger and successful involvement of EU-13
Better health and care, economic growth and sustainable health systems

Personalised medicine – innovative healthcare industry – global health – sustainable and evidence – based health and care systems

Decoding the role of the overall environment for health and well-being

Human exposome – global changes and health

Digital transformation in Health and Care

eHealth and mHealth – ICT for Active and Healthy Ageing

Trusted Big Data solutions and Cybersecurity for Health and Care
Strategic Initiatives around HEALTH

Innovative Medicines Initiative 2
www.imi.europa.eu

European Innovation Partnership on Active and Healthy Ageing
https://webgate.ec.europa.eu/eipaha

Active and Assisted Living 2
www.aal-europe.eu

European & Developing Countries Clinical Trials Partnership (EDCTP2)
www.edctp.org
IMI 2 budget

€3.276 bn

Partnership 2014 - 2024

€1.638 bn

EFPIA = European Federation of Pharmaceutical Industries and Associations

+ other Companies*

* Imaging, Diagnostics, IT for health etc.

www.apre.it
The IMI portfolio

Corporate contribution

IMI funding

Partners

- AriCurs
- Animal Health
- Division of Sanofi
- Astellas
- AstraZeneca
- Basilea
- Boehringer Ingelheim
- Cubist
- GSK
- Janssen
- Lundbeck
- Merck

- Johnson & Johnson
- MedImmune
- Merck
- Merck Sharp & Dohme Corp
- Merial
- Novartis
- Pfizer
- RemPhex
- Sanofi

- AstraZeneca
- Bayer
- Janssen
- Lundbeck
- Merck
- Novartis
- Pfizer
- Sanofi
- UCB

Projects

- € 756,906,619
  - Infectious diseases - 39%

- € 213,636,872
  - Drug discovery - 11%

- € 186,102,324
  - Brain disorders - 10%

- € 118,189,462
  - Metabolic disorders - 6%

- € 116,287,312
  - Drug safety - 6%

- € 76,872,548
  - Stem cells - 4%

- € 74,345,401
  - Data management 4%

- € 74,004,854
  - Inflammatory disorders

- € 30,531,192
  - Sustainable chemistry

- € 20,462,255
  - Drug delivery

- € 18,118,249
  - Drug kinetics

- € 38,994,264
  - Education and training

- € 39,901,138
  - Lung diseases

- € 49,310,000
  - Geriatrics

- € 55,930,954
  - Biologicals

- € 68,069,432
  - Inflammatory disorders

- € 14,910,397
  - Relative effectiveness

- € 1,952,573,292

Website: www.apre.it
Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes/Metabolic disorders
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines

Aligned with WHO priorities
A Typical IMI Consortium

Private Investment *in kind* (€ 1 billion)

EU Public Funding *cash* (€ 1 billion)
Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises (≤ €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:
- EU Member States
- Associated Countries

New! At least three legal entities

Other countries:
No funding unless
- participation deemed essential by IMI for carrying out the action
- Annual Work Plan / Calls documents

IMI partner search tool: https://cloud.imi.europa.eu/web/eimi-pst
IMI 2 – Call 8 includes the following topic:

- Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks

The indicative budget for the entire period of 2 years is €70 million.

IMI 2 – Call 10 will includes the following topics:

Deadline 28 March 2017:

- Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
- How big data could support better diagnosis and treatment outcomes for prostate cancer
- Improving the care of patients suffering from acute or chronic pain
- Creation of a pan-European pediatric clinical trials network
- Biomanufacturing 2020: Development of innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
- Unlocking the solute carrier gene-family for effective new therapies
- Enhanced patient voice in medicines lifecycle
- Precision medicines approaches in autism spectrum disorders

IMI 2 – Call 11 - topic under consideration:

- Exploitation of IMI Project Results
Stay in touch

- Visit our website www.imi.europa.eu
- Sign up to our newsletter bit.ly/IMInewsletter
- Follow us on Twitter @IMI_JU
- Join our LinkedIn group bit.ly/LinkedInIMI
- E-mail us infodesk@imi.europa.eu
DG SANTE
Third Health Programme 2014-2020
Il programma si concentra su **quattro obiettivi principali**, il cui scopo è conseguire un forte potenziale di crescita economica grazie al miglior stato di salute:

1) **Sviluppare strumenti e meccanismi comuni a livello dell'UE per affrontare la carenza** di risorse umane e finanziarie, al fine di **contribuire a sistemi sanitari innovativi e sostenibili**;

2) **Migliorare l'accesso alle competenze mediche e alle informazioni concernenti patologie specifiche** anche su scala transnazionale e **sviluppare soluzioni condivise e orientamenti per migliorare la qualità della sanità e della sicurezza dei pazienti.**

3) **Individuare, diffondere e promuovere l'adozione di buone pratiche convalidate** per **prevenire le malattie e promuovere la buona salute.**

4) **Sviluppare approcci comuni per proteggere i cittadini dalle minacce sanitarie transfrontaliere.**

**http://ec.europa.eu/health/programme/policy/index_en.htm**
CHI NE BENEFICIERÀ E COME

**Direttamente:** tutte le amministrazioni pubbliche nazionali ed europee attive nell'assistenza sanitaria, e gli organismi privati, le ONG e i gruppi di interesse che promuovono politiche e sistemi sanitari più adatti alle attuali sfide demografiche e sociali.

**Indirettamente:** tutti gli europei, grazie a una migliore assistenza sanitaria, alla promozione della salute e a misure di prevenzione.

La partecipazione è aperta ad una vasta gamma di organizzazioni, tra cui:

- Gli Istituti di Ricerca, Università e Ospedali
- Gli enti pubblici
- ONG
- Imprese Commerciali

The EU grant is limited to a **maximum co-funding rate of 60% of eligible costs**. In case of exceptional utility up to 80% can be granted (see Work Plan 2016, Annex VII).

Le dotazioni finanziarie per l'attuazione del programma per il periodo dal 1° gennaio 2014 al 31 dicembre 2020 ammonterranno a **449,4 milioni di EUR**.
<table>
<thead>
<tr>
<th>TITLE</th>
<th>Deadline: 2\textsuperscript{nd} June 2016</th>
<th>INDICATIVE AMOUNT, EUR</th>
<th>Ref. in Work Plan 2016</th>
<th>Grants foreseen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Migrants’ health: Best practices in care provision for vulnerable</td>
<td></td>
<td>4.500.000</td>
<td>2.1.1.1</td>
<td>one or more</td>
</tr>
<tr>
<td>migrants and refugees</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gathering knowledge and exchanging best practices on measures</td>
<td></td>
<td>1.200.000</td>
<td>2.1.1.2</td>
<td>one or more</td>
</tr>
<tr>
<td>reducing underage drinking and heavy episodic drinking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gathering knowledge and exchanging best practices to on measures</td>
<td></td>
<td>600.000</td>
<td>2.1.1.3</td>
<td>one or more</td>
</tr>
<tr>
<td>to prevent illicit drug use in line with the minimum quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>standards in drug demand reduction</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support to Member States and stakeholders to address the chronic</td>
<td></td>
<td>2.500.000</td>
<td>2.1.1.4</td>
<td>one or more</td>
</tr>
<tr>
<td>disease challenge</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donor selection and protection</td>
<td></td>
<td>550.000</td>
<td>2.1.4.3</td>
<td>one or more</td>
</tr>
</tbody>
</table>
Bando aperto
Deadline: 21 Marzo 2017

Rare diseases - Support for new registries

The objective of this call is to provide financial support to the development of 3-4 new registries on rare diseases based on existing registries in Member States, while fully respecting data protection.

Come partecipare?

Vi interessa partecipare al programma per la salute? Tutte le informazioni, insieme al modulo di candidatura, sono disponibili qui: Agenzia Esecutiva per i Consumatori, Salute, Agricoltura e Alimentazione - CHAFEA

Il referente nel nostro paese

Contattate il referente nel vostro paese per ottenere assistenza e consigli:

**Punto focale nazionale**
Dr Giovanni NICOLETTI
Ministero della Salute
nfp_eahc@sanita.it

Per ulteriori informazioni:

Database progetti finanziati:
Active & Healthy Ageing
A European Innovation Partnership
European Innovation Partnership on Active & Healthy Ageing

crosscutting, connecting & engaging stakeholders across sectors, from private & public sector

+2 HLY by 2020
*Triple win for Europe*

---

**Action Groups**

- Improving prescriptions and adherence to treatment
- Better management of health: preventing falls
- Preventing functional decline & frailty
- Integrated care for chronic conditions, inc. telecare
- ICT solutions for independent living & active ageing
- Age-friendly cities and environments

---

**Pillar I**
- Prevention screening early diagnosis

**Pillar II**
- Care & cure

**Pillar III**
- Independent living & active ageing

---

sustainable & efficient care systems
growth & expansion of EU industry

health & quality of life of European citizens
I settori d'intervento prioritari sono stati individuati nel piano strategico di attuazione e nel piano operativo, adottati nel 2011 dal gruppo direttivo incaricato dell'avvio e dell'attuazione della partnership.

Per realizzare il piano tutti i soggetti interessati hanno iniziato a collaborare nell'ambito di gruppi d'azione.

- Action Group A1: Prescription and adherence action at regional level.
- Action Group B3: Integrated care for chronic diseases, including remote monitoring at regional level.
- Action Group C2: Interoperable independent living solutions.
- Action Group D4: Age friendly buildings, cities and environments.

Stakeholders wishing to get involved in the advancing of Specific Actions have formed Action Groups through the "Invitation for Commitment" application process.

In each Action Group, stakeholders commit to running a number of activities, contributing towards the headline target, starting with the creation and implementation of an Action Plan.
E' attivo online anche un "**Marketplace per idee innovative**", che rientra in EIP.

E' uno spazio interattivo per scambiare opinioni, trovare partners o iniziative al fine di mettere in pratica delle idee innovative:  

**Per ulteriori Informazioni:**  
<table>
<thead>
<tr>
<th>ERA-Nets finanziate in Horizon 2020 con partecipazione italiana</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E-Rare-3</strong></td>
</tr>
<tr>
<td><strong>ERACoSysMed</strong></td>
</tr>
<tr>
<td><strong>JPco-fuND</strong></td>
</tr>
<tr>
<td><strong>TRANSCAN-2</strong></td>
</tr>
<tr>
<td><strong>ERA-CVD</strong></td>
</tr>
<tr>
<td><strong>JPI-EC-AMR</strong></td>
</tr>
<tr>
<td><strong>NEURON Cofund</strong></td>
</tr>
</tbody>
</table>
## RATEO DI SUCCESSO Complessivo SC1 Bandi 2014-2015-2016

<table>
<thead>
<tr>
<th>No. topics</th>
<th>Budget Mill. EUR</th>
<th>Proposte presentate</th>
<th>Proposte finanziate</th>
<th>Tasso di successo</th>
</tr>
</thead>
<tbody>
<tr>
<td>72</td>
<td>1.438,7</td>
<td>2.806</td>
<td>257</td>
<td>9,15%</td>
</tr>
</tbody>
</table>

### Partecipazione

<table>
<thead>
<tr>
<th>No. Partecipanti italiani in proposte presentate</th>
<th>No. Partecipanti italiani finanziati</th>
<th>Tasso di successo partecipanti Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.061</td>
<td>274</td>
<td>8,9%</td>
</tr>
</tbody>
</table>

### Coordinamento

<table>
<thead>
<tr>
<th>No. Proposte presentate a coordinamento italiano</th>
<th>No. Coordinamenti italiani finanziati</th>
<th>Tasso di successo coordinatori Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td>375 (13,3% del totale EU)</td>
<td>18</td>
<td>4,8%</td>
</tr>
</tbody>
</table>